US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Quantum Biopharma Ltd.

7.08

+0.17002.46%

Post-market: 7.140.0600+0.85%19:54 EDT

Volume:49.87K

Turnover:350.88K

Market Cap:16.28M

PE:-0.57

High:7.24

Open:6.77

Low:6.77

Close:6.91

Loading ...

Overview Company News Filings

Psychedelic: Clearmind completes clinical site initiations for AUD trial

Press Release: Quantum Biopharma Announces Advocate Against Naked Short Selling and Stock Manipulation, Kevin Malone Appointed as Board Advisor

Quantum BioPharma Corporate Update

Quantum Biopharma Wins Reconsideration Motion by Dr. Raza Bokhari at the Court of Appeal for Ontario

Quantum BioPharma Licensee Celly Nutrition Announces Landmark Partnership with the Asian American Trade Associations Council (AATAC) to Expand Retail Availability of its Alcohol Detox Beverage unbuzzd™

Quantum BioPharma Licensee Celly Nutrition Launches unbuzzd in Puerto Rico

Quantum Biopharma to Jointly Study Demyelination Imaging Technique With Massachusetts Hospital

MT Newswires Live

Quantum BioPharma Announces Joint Clinical Study With Massachusetts General Hospital Scientists to Validate a Novel Positron Emission Tomography (PET) Imaging Technique to Monitor Demyelination In Multiple Sclerosis

Quantum BioPharma Provides Corporate Update

Quantum BioPharma Ltd expected to post a loss of 37 cents a share - Earnings Preview

Quantum Biopharma 2024 Loss Narrows; Shares Jump

MT Newswires Live

Press Release: Quantum Biopharma's 2024 Financial Statements Show Strong Improvements in Cash, Working Capital, Operating Efficiency and the Removal of Material Uncertainty Related to Going Concern

Quantum Group appoints Lynch to board of directors

Press Release: Quantum Biopharma Announces Leading Crusader Against Naked Short Selling and Stock Manipulation, Terry Lynch Elected to Board of Directors

Quantum BioPharma Ltd expected to post a loss of 80 cents a share - Earnings Preview

Psychedelic: Exclusive talk with biotech company Clearmind Medicine

Press Release: Quantum BioPharma Continues to Grow Its Crypto Assets and Diversify Its Treasury With the Purchase of Another USD $1,500,000 Worth of Bitcoin (BTC) and Other Cryptocurrencies

Quantum BioPharma Unaware of Any Material Change

Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial

Quantum BioPharma Provides Corporate Update

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/QNTM/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"QNTM","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"QNTM\",,,,,undefined,":{"symbol":"QNTM","market":"US","secType":"STK","nameCN":"Quantum Biopharma Ltd.","latestPrice":7.08,"timestamp":1745611200000,"preClose":6.91,"halted":0,"volume":49869,"hourTrading":{"tag":"盘后","latestPrice":7.14,"preClose":7.08,"latestTime":"19:54 EDT","volume":139,"amount":985.9995,"timestamp":1745625280430},"delay":0,"floatShares":1944300,"shares":2299514,"eps":-12.492258,"marketStatus":"Closed","change":0.17,"latestTime":"04-25 16:00:00 EDT","open":6.77,"high":7.2407,"low":6.77,"amount":350877.7504017,"amplitude":0.068119,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-12.492258,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745827200000},"marketStatusCode":5,"adr":0,"exchange":"NASDAQ","adjPreClose":6.91,"preHourTrading":{"tag":"盘前","latestPrice":6.755,"preClose":6.91,"latestTime":"08:40 EDT","volume":1,"amount":6.755,"timestamp":1745584851848},"postHourTrading":{"tag":"盘后","latestPrice":7.14,"preClose":7.08,"latestTime":"19:54 EDT","volume":139,"amount":985.9995,"timestamp":1745625280430},"volumeRatio":0.841168},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"QNTM\",,,,,undefined,":{"symbol":"QNTM","floatShares":1944300,"roa":"-58.31%","roe":"-127.76%","lyrEps":-12.492258,"volumeRatio":0.841168,"shares":2299514,"dividePrice":0,"high":7.2407,"amplitude":0.068119,"preClose":6.91,"low":6.77,"week52Low":2.7,"pbRate":"1.42","week52High":33.8,"institutionHeld":0,"latestPrice":7.08,"eps":-12.492258,"divideRate":0,"volume":49869,"delay":0,"ttmEps":-12.492258,"open":6.77,"prevYearClose":3.68,"prevWeekClose":6.3,"prevMonthClose":7.71,"prevQuarterClose":7.71,"fiveDayClose":6.3,"twentyDayClose":8.38,"sixtyDayClose":2.94},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"QNTM\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2530215933","title":"Psychedelic: Clearmind completes clinical site initiations for AUD trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2530215933","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530215933?lang=en_us&edition=fundamental","pubTime":"2025-04-25 23:30","pubTimestamp":1745595026,"startTime":"0","endTime":"0","summary":"In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on site initiations, dosing completion and clinical site partnerships.Discover outperforming stocks and invest smarter with Top Smart Score Stocks.Filter, analyze, and streamline your search for investment opportunities using  Tipranks' Stock Screener.“AUD remains one of the most urgent and underserved public health challenges globally,” said Dr. Adi Zuloff-Shani, CEO. “With millions affected and current treatments often falling short, the study initiation for our FDA-approved CMND-100 trial marks a critical step toward potentially transforming the treatment landscape for alcoholism. We are honored to collaborate with world renowned institutions such as Yale and Johns Hopkins as we advance our mission to potentially provide safe, effective, and innovative solutions for individuals those suffering from alcoholism.”“Completing dosing of all participants in Part A of our 005 tria","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/psychedelic-clearmind-completes-clinical-initiations-153026935.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/psychedelic-clearmind-completes-clinical-initiations-153026935.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MIRA","FLHLF","CMPS","RLMD","MDXXF","BK4547","PSYGF","QNTM","BK4202","SEEL","KTTA","CMND","ENVB","PBM","BK4007","BK4539","ALID","AGNPF","IXHL","OPTHF","NUMIF","CYBN","NRXP","RVVTF","SPRC","PHRRF","BK4168","BK4139","DRUG","ENTBF","MNMD","ATAI","MYCOF","GHRS","SILO","BETRF","SNPX"],"gpt_icon":0},{"id":"2529058371","title":"Press Release: Quantum Biopharma Announces Advocate Against Naked Short Selling and Stock Manipulation, Kevin Malone Appointed as Board Advisor","url":"https://stock-news.laohu8.com/highlight/detail?id=2529058371","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529058371?lang=en_us&edition=fundamental","pubTime":"2025-04-22 19:00","pubTimestamp":1745319600,"startTime":"0","endTime":"0","summary":"Quantum Biopharma Announces Advocate Against Naked Short Selling and Stock Manipulation, Kevin Malone Appointed as Board Advisor. TORONTO, April 22, 2025  -- Quantum BioPharma Ltd.    , is pleased to announce the appointment of Kevin Malone as an advisor to the Board of Directors. Mr. Malone brings a vast wealth of successful stock trading experience, especially in manipulated companies, from his years of wealth management.Mr. Malone is a 2nd generation financial advisor with over 40 years of family experience in wealth management. This combined with his deep entrepreneurial background he launched Malone Wealth in 2021. Mr. Malone focuses deeply on pattern recognition skills and data research to differentiate himself from other financial advisors.Zeeshan Saeed, CEO of Quantum BioPharma said, \"We are thrilled and honored to welcome Kevin Malone as an advisor. His wealth of experience, especially in naked short squeeze strategies, will be an incredible addition to our team of experts fig","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4099","BK4585","QNTM","BK4596","BK4604","LCID","TM","BK4555","BK4588","03160","BK4007","BK4551"],"gpt_icon":1},{"id":"2528041810","title":"Quantum BioPharma Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2528041810","media":"Newsfile","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528041810?lang=en_us&edition=fundamental","pubTime":"2025-04-19 08:00","pubTimestamp":1745020800,"startTime":"0","endTime":"0","summary":"Toronto, Ontario-- - Quantum BioPharma Ltd.     , a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, today announced the following corporate updates.The Company announces the grant of 60,000 restricted share units  pursuant to the Company's equity incentive plan, which are subject to certain vesting criteria. All of the RSUs  are subject to a four month and one day hold period pursuant to the policies of the Canadian Securities Exchange  and applicable securities laws.The Company also announces that the board of directors of the Company  authorized and approved the settlement of outstanding debt owed to arm's length parties by issuing Class B Shares at a deemed price of US$6.75 per Class B Share. The Class B Shares upon issuance will be subject to a four month and one day ho","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/quantum-biopharma-corporate-000000382.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/quantum-biopharma-corporate-000000382.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4099","QNTM","BK4596","BK4007","LCID","BK4551","BK4555"],"gpt_icon":0},{"id":"2527615948","title":"Quantum Biopharma Wins Reconsideration Motion by Dr. Raza Bokhari at the Court of Appeal for Ontario","url":"https://stock-news.laohu8.com/highlight/detail?id=2527615948","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527615948?lang=en_us&edition=fundamental","pubTime":"2025-04-14 19:30","pubTimestamp":1744630200,"startTime":"0","endTime":"0","summary":"Awards in favour of Quantum BioPharma Totalling $180,000 upheld and is now due. TORONTO, April 14, 2025  -- Quantum BioPharma Ltd.     , a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, today announced that the reconsideration motion by Dr. Raza Bokhari at the Court of Appeal for Ontario was dismissed entirely in favour of Quantum BioPharma. Dr. Raza Bokhari, current CEO of Medicus Pharma, Ltd., was CEO of FSD Pharma Inc.   now Quantum BioPharma, in 2019 and was terminated for cause in July 2021.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/quantum-biopharma-wins-reconsideration-motion-113000668.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4551","LCID","BK4007","BK4555","BK4596","QNTM","BK4099"],"gpt_icon":1},{"id":"2526855774","title":"Quantum BioPharma Licensee Celly Nutrition Announces Landmark Partnership with the Asian American Trade Associations Council (AATAC) to Expand Retail Availability of its Alcohol Detox Beverage unbuzzd™","url":"https://stock-news.laohu8.com/highlight/detail?id=2526855774","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526855774?lang=en_us&edition=fundamental","pubTime":"2025-04-10 19:30","pubTimestamp":1744284600,"startTime":"0","endTime":"0","summary":"TORONTO, April  10, 2025  (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), today announced its licensee – Celly Nutrition Corpo","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/10/3059144/0/en/Quantum-BioPharma-Licensee-Celly-Nutrition-Announces-Landmark-Partnership-with-the-Asian-American-Trade-Associations-Council-AATAC-to-Expand-Retail-Availability-of-its-Alcohol-Deto.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LCID","BK4117","BK4211","BK4007","BK4107","BK4555","BK4551","LARK","BK4596","BK4099","AFG","QNTM"],"gpt_icon":0},{"id":"2524230516","title":"Quantum BioPharma Licensee Celly Nutrition Launches unbuzzd in Puerto Rico","url":"https://stock-news.laohu8.com/highlight/detail?id=2524230516","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524230516?lang=en_us&edition=fundamental","pubTime":"2025-04-03 19:00","pubTimestamp":1743678000,"startTime":"0","endTime":"0","summary":"Alcohol Detoxification and Anti-Hangover Beverage (Available on amazon.com and unbuzzd.com) to be Distributed by FUSION in Puerto Rico and Caribbean Region TORONTO, April  03, 2025  (GLOBE NEWSWIRE) -","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/03/3054974/0/en/Quantum-BioPharma-Licensee-Celly-Nutrition-Launches-unbuzzd-in-Puerto-Rico.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4099","BK4551","BK4596","QNTM","BK4555"],"gpt_icon":1},{"id":"2524150713","title":"Quantum Biopharma to Jointly Study Demyelination Imaging Technique With Massachusetts Hospital","url":"https://stock-news.laohu8.com/highlight/detail?id=2524150713","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524150713?lang=en_us&edition=fundamental","pubTime":"2025-04-01 16:23","pubTimestamp":1743495825,"startTime":"0","endTime":"0","summary":"Quantum Biopharma  said Tuesday it entered into a joint clinical study with the Massachusetts General Hospital to investigate an imaging technique to monitor demyelination in people suffering from multiple sclerosis.The parties aims to validate a novel positron emission tomography, or PET, biomarker to monitor myelin integrity and measure demyelination. Multiple sclerosis is a chronic disease of the central nervous system.The financial terms of the collaboration weren't disclosed.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["QNTM","BK4007"],"gpt_icon":0},{"id":"2524130734","title":"Quantum BioPharma Announces Joint Clinical Study With Massachusetts General Hospital Scientists to Validate a Novel Positron Emission Tomography (PET) Imaging Technique to Monitor Demyelination In Multiple Sclerosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2524130734","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524130734?lang=en_us&edition=fundamental","pubTime":"2025-04-01 14:00","pubTimestamp":1743487200,"startTime":"0","endTime":"0","summary":"TORONTO, April  01, 2025  (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) “Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a p","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/01/3052978/0/en/Quantum-BioPharma-Announces-Joint-Clinical-Study-With-Massachusetts-General-Hospital-Scientists-to-Validate-a-Novel-Positron-Emission-Tomography-PET-Imaging-Technique-to-Monitor-De.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1720051017.SGD","LU2089284900.SGD","BK4551","BK4555","BK4099","LU0225283273.USD","LU0320765646.SGD","BK4581","LCID","LU2023251221.USD","LU0006306889.USD","BK4588","LU2111349929.HKD","BK4127","LU1989772840.SGD","LU2347655156.SGD","BK4504","IE00BZ1G4Q59.USD","LU1720051108.HKD","BK4596","LU1732799900.SGD","LU0971096721.USD","LU2028103732.USD","LU0912757837.SGD","BK4192","BK4585","LU1363072403.SGD","LU0795875086.SGD","LU1162221912.USD","LU0158827781.USD","LU2089283258.USD","JYNT","LU0098860793.USD","LU2133065610.SGD","IE00BKVL7J92.USD","PET","LU0314104364.USD","LU0267386448.USD","LU0795875169.SGD","LU1074936037.SGD","LU0106261372.USD","LU1989772923.USD","QNTM","LU1732800096.USD","LU2357305700.SGD","BK4007","BK4534","LU2271345857.HKD","BK4516","BK4185"],"gpt_icon":0},{"id":"2523463939","title":"Quantum BioPharma Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2523463939","media":"Newsfile","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523463939?lang=en_us&edition=fundamental","pubTime":"2025-03-31 07:00","pubTimestamp":1743375600,"startTime":"0","endTime":"0","summary":"Toronto, Ontario-- - Quantum BioPharma Ltd.    , a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced it has renewed the services of King Tide Media LLC based at 806E Windward Way, Suite 816, Lake Worth, Florida for a 1-month term commencing April 1, 2025 for US$15,000 and IR Agency LLC based at 23 Downing Street, Newark NJ 07105, commencing April 1, 2025 for 60 days for US$50,000.This press release contains certain \"forward-looking statements\" within the meaning of applicable Canadian securities law. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance  are not statements of historical fact and may be forward-looking statem","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/quantum-biopharma-provides-corporate-230000648.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/quantum-biopharma-provides-corporate-230000648.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4551","BK4099","BK4007","LCID","QNTM","BK4555","BK4596"],"gpt_icon":0},{"id":"2523490680","title":"Quantum BioPharma Ltd  expected to post a loss of 37 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2523490680","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523490680?lang=en_us&edition=fundamental","pubTime":"2025-03-29 04:13","pubTimestamp":1743192791,"startTime":"0","endTime":"0","summary":"Quantum BioPharma Ltd  expected to post a loss of37cents a share - Earnings Preview Quantum BioPharma Ltd QNTM.CD  is expected to report resultson March 28 for the period ending March 31 2025The Toron","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250328:nL5N3QB1QS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNTM"],"gpt_icon":0},{"id":"2522189501","title":"Quantum Biopharma 2024 Loss Narrows; Shares Jump","url":"https://stock-news.laohu8.com/highlight/detail?id=2522189501","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522189501?lang=en_us&edition=fundamental","pubTime":"2025-03-28 23:08","pubTimestamp":1743174512,"startTime":"0","endTime":"0","summary":"Quantum Biopharma  reported a 2024 net loss of $14.9 million, narrowing from the loss of $18.2 million a year earlier.Cash and cash equivalents were $12.1 million as of December 31, compared with $11.1 million a year earlier, the company said Friday in a statement.A \"strong balance sheet and overall progress\" enabled the company to remove its \"material uncertainty related to going concern\" designation, according to the statement. \"Management believes there is sufficient cash on hand to sustain basic operations beyond January 2027.\"The company's shares jumped 35% in recent Friday trading.Price: 11.28, Change: +2.90, Percent Change: +34.59","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["QNTM","BK4007"],"gpt_icon":0},{"id":"2522543762","title":"Press Release: Quantum Biopharma's 2024 Financial Statements Show Strong Improvements in Cash, Working Capital, Operating Efficiency and the Removal of Material Uncertainty Related to Going Concern","url":"https://stock-news.laohu8.com/highlight/detail?id=2522543762","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522543762?lang=en_us&edition=fundamental","pubTime":"2025-03-28 16:30","pubTimestamp":1743150600,"startTime":"0","endTime":"0","summary":"Quantum Biopharma's 2024 Financial Statements Show Strong Improvements in Cash, Working Capital, Operating Efficiency and the Removal of Material Uncertainty Related to Going Concern. Completion of unbuzzd Clinical Trial and Multiple Sclerosis Drug Lucid-21-302 Phase 1 Trial Advance Company's Pipeline of Products and Assets. TORONTO, March 28, 2025  -- Quantum BioPharma Ltd.    , has reported its financial and operational results for the fourth quarter and year ended December 31, 2024.Fourth Quarter and Full Year 2024 Financial Results. The company's strong balance sheet and overall progress enabled it to remove its Material Uncertainty Related to Going Concern. Management is confident that there is sufficient working capital as of December 31, 2024 to carry out its operations over the next twelve months. Management believes there is sufficient cash on hand to sustain basic operations beyond January 2027.For the year ended December 31, 2024, Operating Expenses were reduced to $16.1 mil","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNTM"],"gpt_icon":1},{"id":"2522002376","title":"Quantum Group appoints Lynch to board of directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2522002376","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522002376?lang=en_us&edition=fundamental","pubTime":"2025-03-27 19:20","pubTimestamp":1743074418,"startTime":"0","endTime":"0","summary":"Quantum BioPharma (QNTM) announces the appointment of Terry Lynch to its board of directors. Lynch will be replacing Dr. Sanjiv Chopra, who has res...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/quantum-group-appoints-lynch-to-board-of-directors?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/quantum-group-appoints-lynch-to-board-of-directors?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","QNTM"],"gpt_icon":0},{"id":"2522375550","title":"Press Release: Quantum Biopharma Announces Leading Crusader Against Naked Short Selling and Stock Manipulation, Terry Lynch Elected to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2522375550","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522375550?lang=en_us&edition=fundamental","pubTime":"2025-03-27 19:00","pubTimestamp":1743073200,"startTime":"0","endTime":"0","summary":"Quantum Biopharma Announces Leading Crusader Against Naked Short Selling and Stock Manipulation, Terry Lynch Elected to Board of Directors. TORONTO, March 27, 2025  -- Quantum BioPharma Ltd.    , is pleased to announce the appointment of Terry Lynch to its board of directors. Mr. Lynch will be replacing Dr. Sanjiv Chopra, who has resigned from his position on the board. The Company thanks Dr. Chopra for his contribution so far. Dr. Chopra will continue to serve as an advisor to the company.Quantum BioPharma  is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcoh","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4596","BK4604","QNTM","BK4099","03160","BK4551","BK4555","TM","BK4588","LCID","BK4007","BK4585"],"gpt_icon":0},{"id":"2522700373","title":"Quantum BioPharma Ltd  expected to post a loss of 80 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2522700373","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522700373?lang=en_us&edition=fundamental","pubTime":"2025-03-25 04:24","pubTimestamp":1742847845,"startTime":"0","endTime":"0","summary":"Quantum BioPharma Ltd  expected to post a loss of80cents a share - Earnings Preview Quantum BioPharma Ltd QNTM.CD  is expected to show a rise in quarterly revenue when it reports  results on March 26 ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250324:nL5N3Q71VM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNTM"],"gpt_icon":0},{"id":"2521172612","title":"Psychedelic: Exclusive talk with biotech company Clearmind Medicine","url":"https://stock-news.laohu8.com/highlight/detail?id=2521172612","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521172612?lang=en_us&edition=fundamental","pubTime":"2025-03-22 22:30","pubTimestamp":1742653811,"startTime":"0","endTime":"0","summary":"In this edition of “Psychedelic”, The Fly conducted an exclusive interview with Mark Haden, vice president of business development at Clearmind Medicine , a psychedelic pharmaceutical biotech company focused on development of therapeutics to solve underserved health problems. Here are some highlights:. Discover stocks' market position with detailed  competitor analyses.“Think of this space as being two overlapping circles, a Venn diagram,” Haden said. “There are addiction treatments, like counseling, Alcoholics Anonymous and some pharmaceutical interventions like Antabuse, naltrexone and acamprosate. I ran an addictions treatment program for 28 years and I can assure you that there is relatively low efficacy, the dropout rate is high, and the treatments tend to be very long-term. That’s the first circle.”“You can take MEAI if you are addicted to alcohol and you don’t want to stop,” Haden said. “You can add MEAI to your alcohol and we believe it will result in people drinking less. It c","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/psychedelic-exclusive-talk-biotech-company-143011967.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/psychedelic-exclusive-talk-biotech-company-143011967.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RVVTF","IXHL","KTTA","BK4139","BK4007","ATAI","PSYGF","CMND","GHRS","QNTM","MDXXF","CMPS","BETRF","MIRA","BK4168","PHRRF","BK4539","MNMD","RLMD","SPRC","BK4547","DRUG","ENTBF","FLHLF","AGNPF","OPTHF","CYBN","NRXP","SILO","SNPX","SEEL","MYCOF","ALID","BK4202","NUMIF","PBM"],"gpt_icon":0},{"id":"2520945833","title":"Press Release: Quantum BioPharma Continues to Grow Its Crypto Assets and Diversify Its Treasury With the Purchase of Another USD $1,500,000 Worth of Bitcoin (BTC) and Other Cryptocurrencies","url":"https://stock-news.laohu8.com/highlight/detail?id=2520945833","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520945833?lang=en_us&edition=fundamental","pubTime":"2025-03-20 19:30","pubTimestamp":1742470200,"startTime":"0","endTime":"0","summary":"Quantum BioPharma Continues to Grow Its Crypto Assets and Diversify Its Treasury With the Purchase of Another USD $1,500,000 Worth of Bitcoin  and Other Cryptocurrencies. TORONTO, March 20, 2025  -- Quantum BioPharma Ltd.    , is pleased to announce that after receiving approval from the Board of Directors, the Company has purchased an additional USD $1,500,000 worth of Bitcoin  and other cryptocurrencies, growing and increasing its crypto assets as part of its strategic efforts. This brings the total amount of Bitcoin , and other cryptocurrencies purchased to USD $3,500,000. As previously announced, the company will continue to allow for future financings and other transactions to be carried out in cryptocurrency.This move reflects the company's belief in the potential of Bitcoin  and other currencies to provide a return on investment for shareholders and to provide some hedge against the dollar. The company is now set up to receive financing in cryptocurrencies as well as executing o","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BTCmain","BK4585","03439","XBTmain","BTC.USD.HKCC","US6M.BOND","US2Y.BOND","QNTM","APT.USD.CC","BK4601","BK4555","BK4551","09042","TON.USD.HKCC","US3Y.BOND","03008","USD","03042","US30Y.BOND","TM","09008","BTC.USD.CC","BK1611","09439","BK4594","BK4596","US5Y.BOND","US7Y.BOND","BK4604","APT.USD.HKCC","BTC","BK4007","TON.USD.CC","US12M.BOND","03160","BK4099","83042","US10Y.BOND"],"gpt_icon":1},{"id":"2520681049","title":"Quantum BioPharma Unaware of Any Material Change","url":"https://stock-news.laohu8.com/highlight/detail?id=2520681049","media":"Newsfile","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520681049?lang=en_us&edition=fundamental","pubTime":"2025-03-18 03:33","pubTimestamp":1742239980,"startTime":"0","endTime":"0","summary":"Toronto, Ontario-- - At the request of the Canadian Investment Regulatory Organization, Quantum BioPharma Ltd.     wishes to confirm that the Company's management is unaware of any material change in the Company's operations that would account for the recent increase in market activity.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/quantum-biopharma-unaware-material-change-193300436.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/quantum-biopharma-unaware-material-change-193300436.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LCID","BK4596","BK4555","QNTM","BK4007","BK4099","BK4551"],"gpt_icon":0},{"id":"2519638156","title":"Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2519638156","media":"TipRanks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519638156?lang=en_us&edition=fundamental","pubTime":"2025-03-14 23:40","pubTimestamp":1741966809,"startTime":"0","endTime":"0","summary":"In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on a dosing initiation, a development expansion and a distribution agreement.Discover stocks' market position with detailed  competitor analyses.MIRA EXPANDS KETAMIR-2 DEVELOPMENT WITH TOPICAL: On Thursday, MIRA Pharmaceuticals  announced the formulation of Ketamir-2 into a topical treatment for localized neuropathic and inflammatory pain. This expands the company’s pain management portfolio beyond its ongoing Ketamir-2 oral treatment for neuropathic pain, offering a novel, targeted approach for localized pain relief. The topical treatment of Ketamir-2 is designed for slow release, delivering targeted pain relief directly at the application site while minimizing systemic exposure and side effects.“The development of both an oral and topical formulation of Ketamir-2 significantly expands our pipeline and enhances the value proposition of MIRA,” stated Erez Aminov, CEO . “By adv","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/psychedelic-atai-reports-dosing-first-154009720.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/psychedelic-atai-reports-dosing-first-154009720.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SEEL","OPTHF","PHRRF","BETRF","QNTM","MYCOF","IXHL","SPRC","BK4547","FLHLF","MDXXF","BK4139","BK4539","ATAI","RLMD","PBM","CMPS","NUMIF","BK4007","MIRA","RVVTF","GHRS","CMND","ALID","AGNPF","SILO","KTTA","ENTBF","DRUG","ENVB","CYBN","PSYGF","MNMD","SNPX","BK4168","NRXP","BK4202"],"gpt_icon":0},{"id":"2517959834","title":"Quantum BioPharma Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2517959834","media":"Newsfile","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517959834?lang=en_us&edition=fundamental","pubTime":"2025-03-08 09:00","pubTimestamp":1741395600,"startTime":"0","endTime":"0","summary":"Toronto, Ontario-- - Quantum BioPharma Ltd.    , a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is pleased to announce the following corporate updates.Effective today, the Company has cancelled an aggregate of 7,692 warrants  to purchase class B subordinate voting shares in the capital of the Company , which were previously granted to Michael  Zapolin. The Company and Mr. Zapolin entered into a warrant cancellation agreement, pursuant to which Mr. Zapolin agreed to cancel the Warrants.Management had reviewed Mr. Zapolin's outstanding Warrants and determined that the Warrants granted to Mr. Zapolin no longer represented a realistic incentive to motivate Mr. Zapolin.The Company also announces the grant of 7,692 stock options to acquire Class B Shares  to Mr. Zapolin  pursuant to the Company's equity incentive plan, with an exercise price of C$6.60 per Class B Share and an expiry date of March 7, 2027.The securities being offered ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/quantum-biopharma-provides-corporate-010000421.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/quantum-biopharma-provides-corporate-010000421.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4551","BK4099","BK4007","LCID","QNTM","BK4555","BK4596"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":50,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/QNTM\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-08-15","symbol":"QNTM","defaultRemindTime":1723728600000,"type":"split","dateTimestamp":1723694400000,"forFactor":65,"toFactor":1,"ratio":65},{"market":"US","date":"2024-08-14","symbol":"QNTM","fiscalQuarterEnding":"2024/06","expectedEps":-0.06,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1723608000000,"reportTimeType":"pre","actualEps":-0.08},{"market":"US","date":"2024-05-14","symbol":"QNTM","fiscalQuarterEnding":"2024/03","expectedEps":-0.05,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715659200000,"reportTimeType":"post","actualEps":-0.05},{"market":"US","date":"2024-03-28","symbol":"QNTM","fiscalQuarterEnding":"2023/12","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1711598400000,"reportTimeType":"post","actualEps":-0.04},{"market":"US","date":"2023-11-14","symbol":"QNTM","fiscalQuarterEnding":"2023/09","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1699938000000,"reportTimeType":"post","actualEps":-0.03}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"QNTM\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"QNTM\",market:\"US\",delay:false,,,undefined,":{"strongBuy":1,"buy":0,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":1,"analysts":1,"updateTime":1733025600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/QNTM\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"QNTM","date":"2025-04-24","current":-1.303484,"percent":0.176471,"low":-2.690643,"twenty":-1.273742,"median":-0.942233,"eighty":-0.700453,"high":-0.546516,"avg":-1.016311,"sd":0.373414,"marketCap":18513021.69},"quantilePoints":[{"date":"2024-08-16","current":-0.603659,"twenty":-0.603659,"median":-0.603659,"eighty":-0.603659,"marketCap":4509122.69},{"date":"2024-08-23","current":-0.69618,"twenty":-0.715087,"median":-0.702389,"eighty":-0.647248,"marketCap":5200216.8},{"date":"2024-08-30","current":-0.852638,"twenty":-0.775012,"median":-0.723053,"eighty":-0.69618,"marketCap":6368904.17},{"date":"2024-09-06","current":-0.700453,"twenty":-0.779153,"median":-0.715087,"eighty":-0.653758,"marketCap":5232131.53},{"date":"2024-09-13","current":-0.690425,"twenty":-0.744955,"median":-0.704525,"eighty":-0.66483,"marketCap":5157233.86},{"date":"2024-09-20","current":-0.993485,"twenty":-0.779153,"median":-0.708429,"eighty":-0.669437,"marketCap":7420982.26},{"date":"2024-09-27","current":-0.939399,"twenty":-0.944216,"median":-0.716816,"eighty":-0.671749,"marketCap":7016975.73},{"date":"2024-10-04","current":-0.974979,"twenty":-0.964556,"median":-0.73591,"eighty":-0.672431,"marketCap":7282751.47},{"date":"2024-10-11","current":-1.090369,"twenty":-0.996068,"median":-0.785363,"eighty":-0.686838,"marketCap":8144673.49},{"date":"2024-10-18","current":-1.45785,"twenty":-1.05098,"median":-0.878475,"eighty":-0.692178,"marketCap":10889624.45},{"date":"2024-10-25","current":-1.442036,"twenty":-1.139524,"median":-0.944288,"eighty":-0.695467,"marketCap":10771499.96},{"date":"2024-10-31","current":-1.205452,"twenty":-1.188827,"median":-0.956387,"eighty":-0.698744,"marketCap":9004299.96},{"date":"2024-11-08","current":-1.349307,"twenty":-1.226202,"median":-0.974979,"eighty":-0.705239,"marketCap":10078847.03},{"date":"2024-11-15","current":-0.935735,"twenty":-1.275577,"median":-0.971909,"eighty":-0.70853,"marketCap":9579098.88},{"date":"2024-11-22","current":-0.960529,"twenty":-1.226202,"median":-0.963485,"eighty":-0.712491,"marketCap":9832911.8},{"date":"2024-11-29","current":-0.869873,"twenty":-1.213599,"median":-0.963485,"eighty":-0.716471,"marketCap":8904877.06},{"date":"2024-12-06","current":-0.815226,"twenty":-1.195279,"median":-0.949234,"eighty":-0.720349,"marketCap":8345447.87},{"date":"2024-12-13","current":-0.759973,"twenty":-1.179109,"median":-0.943869,"eighty":-0.728196,"marketCap":7779827.58},{"date":"2024-12-20","current":-0.685739,"twenty":-1.175332,"median":-0.939333,"eighty":-0.720349,"marketCap":7019890.91},{"date":"2024-12-27","current":-0.616825,"twenty":-1.165719,"median":-0.934788,"eighty":-0.708463,"marketCap":6314424.32},{"date":"2025-01-03","current":-0.759721,"twenty":-1.141743,"median":-0.927085,"eighty":-0.708429,"marketCap":7777249.84},{"date":"2025-01-10","current":-0.742133,"twenty":-1.141141,"median":-0.878991,"eighty":-0.708564,"marketCap":7597197.4},{"date":"2025-01-17","current":-0.619978,"twenty":-1.139524,"median":-0.852638,"eighty":-0.692178,"marketCap":6346706.26},{"date":"2025-01-24","current":-0.619485,"twenty":-1.109884,"median":-0.815226,"eighty":-0.676014,"marketCap":6341654.9},{"date":"2025-01-31","current":-0.561714,"twenty":-1.082749,"median":-0.80554,"eighty":-0.668876,"marketCap":5750259.21},{"date":"2025-02-07","current":-2.690643,"twenty":-1.13989,"median":-0.808855,"eighty":-0.664161,"marketCap":27544054.02},{"date":"2025-02-14","current":-1.986183,"twenty":-1.178654,"median":-0.820792,"eighty":-0.668876,"marketCap":20332510.29},{"date":"2025-02-21","current":-1.288506,"twenty":-1.229787,"median":-0.861255,"eighty":-0.670874,"marketCap":13190405.23},{"date":"2025-02-28","current":-0.926203,"twenty":-1.213599,"median":-0.879508,"eighty":-0.672308,"marketCap":9481520.11},{"date":"2025-03-07","current":-0.836122,"twenty":-1.195279,"median":-0.874174,"eighty":-0.673618,"marketCap":8559365.07},{"date":"2025-03-14","current":-0.835912,"twenty":-1.179109,"median":-0.852638,"eighty":-0.675778,"marketCap":8557218.89},{"date":"2025-03-21","current":-1.273806,"twenty":-1.21489,"median":-0.874174,"eighty":-0.680186,"marketCap":13039931.07},{"date":"2025-03-28","current":-1.564993,"twenty":-1.229787,"median":-0.90884,"eighty":-0.687613,"marketCap":16020800.96},{"date":"2025-04-04","current":-1.52667,"twenty":-1.237788,"median":-0.92592,"eighty":-0.691301,"marketCap":21682873.03},{"date":"2025-04-11","current":-1.273742,"twenty":-1.263262,"median":-0.933841,"eighty":-0.694042,"marketCap":18090602.39},{"date":"2025-04-17","current":-1.168311,"twenty":-1.270743,"median":-0.939267,"eighty":-0.697035,"marketCap":16593197.2},{"date":"2025-04-24","current":-1.303484,"twenty":-1.273742,"median":-0.942233,"eighty":-0.700453,"marketCap":18513021.69}],"updateTime":1745614401487}}}